NasdaqGS:BEAMBiotechs
Assessing Beam Therapeutics (BEAM) Valuation After New Patent Agreement Secures Base Editing IP Access
Patent agreement puts Beam Therapeutics (BEAM) intellectual property in focus
Beam Therapeutics (BEAM) has moved to secure its gene editing toolkit, signing a standby license agreement with Kobe University and Bio Palette that aims to protect access to key base editing patents.
See our latest analysis for Beam Therapeutics.
The standby license news lands after a choppy year, with a 26.79% 90 day share price return but a 1 year total shareholder return of 13.83% decline, signaling near term...